Company updateBusinessLine
Biocon's Pebrilzo gets first EMA tailored pathway approval
Positive+40
GreyOak summary
Biocon Ltd received marketing authorisation from the European Commission for Pebrilzo, a pertuzumab biosimilar. This marks the first approval under the EMA's new tailored clinical pathway. The drug is indicated for treating HER2-positive breast cancer across multiple stages in the European Union.
What it affects
- BioconBIOCONPositive +40
Received EMA approval for Pebrilzo biosimilar.Rolling sentiment Positive +22
Source
Read the original at BusinessLineMore Biocon news
- Biocon gets European Commission's market authorisation for biosimilar for breast cancer treatmentCNBC-TV18 · Company update ·
- Biocon gets EU nod for Pebrilzo breast cancer drugBusiness Standard · Company update ·